Skip to main content
. 2017 Jan 25;2(5):556–560. doi: 10.1001/jamacardio.2016.5395

Figure 2. Levels of Circulating Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) and Placebo-Controlled Percentage Reductions in Low-Density Lipoprotein Cholesterol (LDL-C) Stratified by Baseline PCSK9 Level.

Figure 2.

Levels of circulating PCSK9 over time in 138 patients in the pharmacokinetic and pharmacodynamic substudy treated with evolocumab 140 mg every 2 weeks (A) or 420 mg monthly (B), stratified by quartile of baseline PCSK9 level. Placebo-controlled, percentage reduction in LDL-C in 3016 patients treated with evolocumab 140 mg every 2 weeks (C) or 420 mg monthly (D), stratified by quartile of baseline PCSK9 level. The error lines represent 95% CIs. LS indicates least squares.